ARTICLE | Finance
Plus fresh cash for Halia and Neophore, and a new spinout from venture-backed Cumulus Oncology
By Paul Bonanos, Director of Biopharma Intelligence
February 2, 2024 1:45 AM UTC
A new fund affiliated with The Column Group will invest $400 million to create single-asset companies shepherded by a dedicated R&D unit. Late Thursday, TCG Labs-Soleil said its model will include an evergreen scientific hub, Soleil, accompanied by a closed-end venture fund called TCG Labs.
Longtime NGM Biopharmaceuticals Inc. (NASDAQ:NGM) CSO Jin-Long Chen will be CEO of Soleil and one of three managing partners at the fund, alongside TCG’s Peter Svennilson and Tim Kutzkey…